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Abstract
Background: Wiskott-Aldrich syndrome is an X-linked recessive immunodeficiency due to mutations in Wiskott-
Aldrich syndrome (WAS) gene. WAS gene is encoded for a multifunctional protein with key roles in actin
polymerization, signaling pathways, and cytoskeletal rearrangement. Therefore, the impaired protein or its absence
cause phenotypic spectrum of the disease. Since identification of novel mutations in WAS gene can help uncover
the exact pathogenesis of Wiskott-Aldrich syndrome, the purpose of this study was to investigate disease causing-
mutation in an Iranian male infant suspicious of this disorder.
Case presentation: The patient had persistent thrombocytopenia from birth, sepsis, and recurrent gastrointestinal
bleeding suggestive of both Wiskott-Aldrich syndrome and chronic colitis in favor of inflammatory bowel disease
(IBD). To find mutated gene in the proband, whole exome sequencing was performed for the patient and its data
showed a novel, private, hemizygous splice site mutation in WAS gene (c.360 + 1G > C).
Conclusions: Our study found a novel, splice-site mutation in WAS gene and help consider the genetic counselling
more precisely for families with clinical phenotypes of both Wiskott-Aldrich syndrome and inflammatory bowel
disease and may suggest linked pathways between these two diseases.
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Background
Wiskott-Aldrich syndrome (WAS), [MIM: 301000],
which is a rare X-linked recessive immunodeficiency is
mainly characterized by thrombocytopenia, eczema,
infection, and bloody diarrhea. The disease usually leads
to death before the age of 10 years [1–3]. Patients with
WAS, usually, suffer from upper and lower respiratory
tract infections, chronic diarrhea, melena and inflamma-
tory bowel disease (IBD). The incidence of WAS
throughout the world is estimated to be 1 to 10 in 1
million live birth per year [4]; however; its prevalence or
incidence in Iran has not been reported yet. The disease
is caused by pathogenic mutations in the WAS gene (lo-
cated on Xp11.22–23) consisted of 12 exons. The gene
is encoded for the Wiskott-Aldrich syndrome protein
(WASp), a cytoplasmic 502–amino acid protein involved
in the signal transduction from cell surface receptors to
the actin cytoskeleton. Its main expression is in
non-erythroid hematopoietic cells, indicating its essential
roles in the function of these cells [5–7]. The WASp is a
multifunctional protein with the key involvement in
actin polymerization, signaling pathways, and cytoskel-
etal rearrangement, which is crucial for the monocytes
and macrophages migration to infection sites and
inflamed tissues, and binding and phagocytosis of anti-
gens [1, 8, 9]. Thus, complete or partial deficiency of
WASp leads to malfunctioning of tissue macrophages,
neutropenia, and small platelet sizes, causing repeated
infections as well as bleeding tendency [4].
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Up to know, more than 431 mutations have been
reported in WAS gene (Human Genome Mutation Data-
base, HGMD, http://www.hgmd.cf.ac.uk). According to
the HGMD database, most of WASp mutations have
occurred within the 4 most N-terminal exons of the
gene with the arginine residue at position 86 accounting
for the most common mutated amino acid in WASP.
Different mutations in this protein can cause variable
severity of the disease. For instance, study conducted by
Greer et al. [10] revealed that the WAS patients with
milder clinical presentations had missense mutations.
Moreover, study conducted by Villa et al. showed that
some WAS mutations can cause only thrombocytopenia
with small-sized platelets [2] but, up to now, it is not
fully understood why specific disease-causing variants
only affect the megakaryocytic cells. In addition, in a
WAS family with thrombocytopenia, increased levels of
serum IgA and mild nephropathy has been observed to
complicate the pathogenesis of this disorder [11]. Since
identification of different mutations in WAS gene may
help understand the pathogenesis of WAS, the aim of
this study was to identify pathogenic variation in our
patient with clinical findings suspicious of WAS.
Case presentation
An 8-month-old Iranian male infant, a product of
consanguineous marriage, was admitted to our center
with history of persistent thrombocytopenia from birth,
sepsis, and recurrent gastrointestinal bleeding. In family
history, the proband had a sibling who died with similar
phenotypes. Initial laboratory findings at different ages
were suggestive of idiopathic thrombocytopenic purpura
(ITP) (Table 1), therefore; intravenous immunoglobulin
(IVIG) was administered for him. At the age of 1 month,
he showed mild skin thickening and bone marrow
aspiration revealed moderate hypo-cellular marrow with
decreased megakaryocyte. However, TORCH study,
rheumatologic work up, and levels of complement
components such as C3, C4, and CH50 were in normal
range. At the age of 4 months, he had increased levels of
erythrocyte sedimentation rate (ESR) and C-reactive pro-
tein (CRP) and decreased levels of hemoglobin (Hb) and
mean platelet volume (MPV), indicating thrombocytopenia.
Therefore, IVIG and platelet were administered for the
patient.
Based on the patient history and clinical and labora-
tory findings described above, WAS disease was clinic-
ally suspected; therefore, we performed immunological
assays. For instance, flow-cytometry showed normal
results but the level of antibodies for IgG, IgA, and IgE
was high (IgM was in normal range) (Table 2). At that
time, to control the sepsis, broad spectrum of antibiotics
(Vancomycin and Meropenem) were administered for
the patient. At the age of 8 months, the patient had poor
feeding, abdominal distension, and lower gastrointestinal
bleeding. At that time, the patient was febrile and he
was in respiratory distress. Generalized skin petechia
and perianal skin tag were also detected. Due to rectal
bleeding, endoscopy and sigmoidoscopy were also per-
formed and results revealed severe erythema, erosion,
and nodularity in antrum of stomach and nodularity and
erythema in the bulb of esophagus. In sigmoidoscopy,
skin tag, fistula, fissure in the perianal area, severe and
diffused ulcer, and polypoid lesion and decreased vascu-
larity in rectum were detected (Fig. 1a). Colon and
rectum biopsy showed chronic colitis with severe activity
in favor of inflammatory bowel disease (Fig. 1b). Histo-
logical examination of biopsies from the patient also
revealed cryptitis and crypt abscesses (Fig. 1c). Since
there was no an infectious etiology, these observations
were in support of chronic colitis and/or IBD. To find
the genetic cause of the disease in our patient, we per-
formed Next Generation Sequencing (NGS) technique
to sequence all exons of protein-coding genes.
Whole Exome Sequencing (WES) using Illumina
NextSeq500 for pair-end 150-nucleotide sequencing was
performed on DNA sample from proband. The NGS
results were analyzed using bioinformatics tools, includ-
ing BWA aligner [12], GATK [13], Annovar [14], and
open access bioinformatics tools. Totally, more than
120 K annotated variants were identified with hetero/
homo ratio of 1.6 to 1.8, which were then filtered based
on their frequency, position, functional consequences,
pattern of inheritance and mainly clinical phenotype.
NGS data of the proband, revealed a novel, private,
hemizygous splice site mutation (NM_000377:ex-
on3:c.360 + 1G > C, Chromosome X) in WAS gene. This
Table 1 Results of complete blood count at different ages of the proband
Age 22 days 40 days 4 months 8 months 12 months
WBC (per mm3) 9200 17,300 3700 6600 12,100
RBC (per mm3) 3.36*10^6 _ 3.35*10^6 2.82*10^6 4.36*10^6
Hb (gr/dl) 10.8 12 6.8 6.6 7.9
MCV (fl) 97 _ 70.4 77 66.5
PLT (per mm3) 45*10^3 130*10^3 64*10^3 53*10^3 212*10^3
MPV (fl) _ 7 6.9 0 6.4
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Table 2 Results of flow cytometry and immunoglobulin study in the proband at the age of 4 months
Test Result Unit Reference
CD3 82.96 % 30–78
CD4 33.78 % 22–58
CD8 8.9 % 10–37
CD4/CD8 3.8 % 1–4
CD16 9.59 % 5–19
CD19 47.84 % 9–38
CD20 45.12 % 3–15
CD56 9.15 % 3–15
Dihydrorhodamine (DH) 90 (Normal Range > 50)
IgG 11.73 g/L 1.8–8.0
IgM 0.615 g/L 0.20–1.0
IgA 1.25 g/L 0.08–0.8
IgE 713 U/L > 10.0-Atopy possible
> 50.0-Atopy high risk
Tetanus Ab IgG 1.43 IU/ml < 0.1 Basic immunisation recommended
0.1–1 To be controlled after 1–2 years
1–5 To be controlled after 2–4 years
> 5.0 To be controlled after 4–8 years
Fig. 1 Sigmoidoscopy study in the proband. a. It is shown severe and diffused ulcer, polypoid lesion and decreased vascularity in rectum. b.
Colon and rectum biopsy revealed chronic colitis. c. The histological section from colon and rectum showed cryptitis and crypt abscesses (Arrow)
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identified mutation was not reported previously, therefore,
is categorized as the variant of unknown significance
(VUS). However, due to lack of any other mutation that
can explain the phenotype in this patient, almost complete
phenotypic correlation between the disease and identified
mutation, and disrupting nature of splice-site mutations,
we believe this is a pathogenic mutation. We will
deposit into the Clinar database (submission number:
SUB3969419). Additionally, as the mutation has no
reported frequency in our database (Bayangene) or any
other available public variant databases, it was considered
as a private mutation.
To confirm the identified novel mutation, genomic
DNA was prepared from whole blood samples of family
members of the proband by QIAamp DNA Blood Mini
Kit (Qiagen, Germany) according to the company’s
protocol. Then, PCR was carried out for the proband
and his parents using following primers: FWAS-E3:
GCTCCCAAATCCAGACAC and RWAS-E3: CTTG
CACTAGAGGACTCAC (PCR product: 561 bp) for
amplification of exon 3 of WAS gene. After that, Sanger
sequencing was performed for PCR products on 3130XL
Genetic Analyzer (Applied Biosystems USA) according
to ABI BigDye Terminator Cycle Sequencing Kit (Ap-
plied Biosystems, USA). Sanger sequencing results were
analyzed with the use of NCBI BLAST and CodonCode
Aligner software in which it confirmed hemizygous sta-
tus in proband, heterozygous in his mother and normal
in his father (Fig. 2). Different bioinformatics software
and websites were also used to identify the features and
the consequences of mutation in the given position of
the protein and also to provide the family pedigree, in-
cluding Human Splicing Finder (HSF, http://
www.umd.be/HSF3/technicaltips.html), STRING (func-
tional protein association networks, https://string-db.org),
and Pedigree Chart Designer from CeGat (https://
www.cegat.de). Following evidences can confirm that this
mutation is led to WAS: 1- WES detected only this muta-
tion to be linked with observed clinical and laboratory
findings suggestive of WAS in the proband. 2- Sanger data
given in Fig. 2, confirmed the presence of the mutation in
the proband as hemizygous, his mother as heterozygous,
and his father as normal, confirming the X-linked segrega-
tion of the disease. 3- Mutation is located within the
donor splice site which is expected to be highly damaging
since another mutation in this nucleotide (c.360 + 1G > T,
with ID number of CS972885 and CS961711in HGMD)
could affect splice site. 4- Using HSF tool, it predicted that
the wild type (WT) splice site will be broken and alter-
ation of the WT donor site, most probably affects splicing.
5- Exon 3 is within WH1 domain which is important for
binding to a Pro-rich ligand; therefore, skipping of this
Fig. 2 Sanger sequencing chromatogram. The proband showed hemizygous c.360 + 1G > C (C/C), his mother as heterozygous (G/C), and his
father as normal (G/G)
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exon can be very damaging and most probably cause the
sever form of the disease [1].
In our study we also used STRING tool to predict the
association network between WAS protein and other
proteins. Its results revealed that WASp has interaction
with several main proteins involved in different bio-
logical pathways and cellular component.
Discussion and conclusion
WASp is a member of WAS family of proteins with
similar domain named proline-rich region (PPP) which
can bind by SH3 domains. WASp has also other essen-
tial domains and with identification of various motifs
and regions across WASp, it has revealed that they can
interact with key proteins in biological pathways. The
domains are regulated by different factors such as
GTPase, Cdc42 (role in the actin filament formation),
ARP2/3 (the cytoskeletal organizing complex), p47nck, a
47-kD cytosolic adapter protein, and tyrosine-protein
kinase Fyn [15, 16]. WASp is considered as a link
between CDC42 and the actin cytoskeleton since in
males affected with WAS, T- lymphocytes show a sever
disruption of actin cytoskeleton, which may be due to
the impaired Cdc42 signaling [16, 17]. Therefore, dysreg-
ulation of pathways linked to WASp have dramatic
effects on different biological processes such as actin
polymerization [16, 18, 19]. As described in result
section, STRING tool showed that WASp has inter-
action with several key proteins, for example ARP2
actin-related protein 2 homolog, yeast, (ACTR2), WAS/
WASL interacting protein family, member 1 (WIPF1),
ARP3 actin-related protein 3 homolog, yeast, (ACTR3),
actin related protein 2/3 complex, subunit 2, (ARPC2),
cell division cycle 42 (GTP binding protein, 25 kDa)
(CDC42), actin related protein 2/3 complex, subunit 3
(ARPC3) and so on. These interactions and associations
with different proteins suggest the possible indirect
involvement of WASp in various pathways and any
interrupted interactions may cause life-threating clinical
phenotypes. Therefore, the study of different mutations
in this gene and functional effects of the mutations help
understand the exact mechanism of this gene in different
pathways, explaining why different mutations in this
gene lead to some specific characterizations of the
disease (for example the identified mutation in our study
resulted in both WAS and chronic colitis with severe
activity in favor of inflammatory bowel disease), and
shed light onto the therapeutic approaches for this dis-
ease through its corresponding pathways.
In summary, a novel donor splice site mutation was
found in WAS gene in our patient who had both WAS
and chronic colitis suggestive of inflammatory bowel
disease. Such researches may help consider the genetic
counselling more precisely for families with clinical
phenotypes suggestive of these diseases and help to un-
cover the biological pathways linked to WAS gene.
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